Xiaohuang Qudan decoction alleviates ANIT-induced cholestatic liver injury by inhibiting the JAK2/STAT3 pathway and regulating TH17/Treg

被引:0
|
作者
Zhangkui Tan [1 ]
Lifeng Chen [1 ]
Zhiqin Ye [2 ]
Qiping Lu [3 ]
机构
[1] Department of Rheumatology and Immunology, General Hospital of Central Theater Command of the People's Liberation Army
[2] Department of Rheumatology, Hubei Provincial Hospital of Traditional Chinese Medicine, affiliated with Hubei University of Chinese Medicine
[3] Department of General Surgery, General Hospital of Central Theater Command of the People's Liberation
关键词
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
摘要
Xiaohuang Qudan decoction(XHQDD) is a classical traditional Chinese medicine(TCM) formula widely used in the treatment of cholestatic liver injury.Despite its widespread use,the protective mechanism of XHQDD against cholestatic liver injury remains incompletely understood.The aim of this study was to investigate whether XHQDD mediates its beneficial effects by inhibiting the Janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3) pathway and regulating TH17/Treg balance.To this end,the researchers used Sprague-Dawley(SD) rats and established a cholestatic liver injury model by oral administration of alpha-naphthylisothiocyanate(ANIT).The experimental group was divided into six groups:Control(CON),ANIT,ursodeoxycholic acid(UDCA),XHQDD-low dose(XHQDD-L)group,XHQDD-medium dose(XHQDD-M) group,and XHQDD-high dose(XHQDD-H) groups.Then,after 7 d of treatment,various tests were performed to verify the results.Firstly,XHQDD and its drug-containing serum were analyzed by ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry(UPLC-MS/MS),and 14 blood-entry components were identified.Then,bile flow was monitored and found to be significantly reduced in the model group,which was significantly reversed in the UDCA and XHQDD groups.To further assess ANIT-induced liver injury,hematoxylin and eosin(H&E) and Sirius red staining,alongside transmission electron microscopy(TEM),were employed to observe liver tissues,revealing hepatocellular injury,cholestasis,and hepatic fibrotic changes.Serum inflammatory factors and liver injury indicators were assessed using enzyme-linked immunosorbent assay(ELISA),indicating an inflammatory state in ANIT-induced liver injury rats.The expression levels of JAK2/STAT3-related genes and proteins in liver and intestinal tissues were measured via quantitative reverse transcription polymerase chain reaction(qRT-PCR),immunohistochemistry,immunofluorescence(IF) staining,and Western blotting(WB)assays.These studies revealed that the inflammatory state of liver-injured rats was inextricably linked to the inflammatory cascade associated with the JAK2/STAT3 pathway and that XHQDD may exert anti-inflammatory efficacy by inhibiting the JAK2/STAT3 pathway.Flow cytometry was used to determine the percentage of T helper 17(Th17)/regulatory T(Treg)cells in serum and hepatocytes,and it was further found that XHQDD was able to regulate Th17/Treg immune homeostasis in liver-injured rats.The findings suggest that XHQDD markedly alleviates inflammation in ANIT rats,potentially treating cholestasis and liver injury through JAK2/STAT3 inhibition and Th17/Treg balance regulation.
引用
收藏
页码:457 / 470
页数:14
相关论文
共 50 条
  • [31] Curcumin Suppresses JAK2/STAT3 Pathway to Ameliorate Pancreatic Injury Induced by Sepsis in Rats
    Zhu, Shuaijun
    Zheng, Danqi
    Weng, Qinyong
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 14 - 21
  • [32] FTY720 attenuates APAP-induced liver injury via the JAK2/STAT3 signaling pathway
    He, Xiangmin
    Kang, Kai
    Pan, Dan
    Sun, Yue
    Chang, Bing
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2022, 49 (05)
  • [33] Erythropoietin alleviates hyperglycaemia-associated inflammation by regulating macrophage polarization via the JAK2/STAT3 signalling pathway
    Cui, Jinjin
    Zhang, Fengyun
    Cao, Wei
    Wang, Yongshun
    Liu, Jingjin
    Liu, Xinxin
    Chen, Tao
    Li, Ling
    Tian, Jinwei
    Yu, Bo
    MOLECULAR IMMUNOLOGY, 2018, 101 : 221 - 228
  • [34] Agrimonolide mitigated DSS-induced colitis by modulating the balance between Treg and Th17 cells through the suppression of the Notch and JAK2/STAT3 signaling pathways
    Jiang, Jie
    Sheng, Yuxiang
    Zheng, Zheng
    Qin, Fuhao
    Jiang, Bin
    HELIYON, 2024, 10 (13)
  • [35] Shuxie-1 Decoction Alleviated CUMS -Induced Liver Injury via IL-6/JAK2/STAT3 Signaling
    Zhang, Mengting
    Wu, Wanhong
    Huang, Caoxin
    Cai, Teng
    Zhao, Nengjiang
    Liu, Suhuan
    Yang, Shuyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Daphnetin ameliorates acute lung injury in mice with severe acute pancreatitis by inhibiting the JAK2–STAT3 pathway
    Shujun Yang
    Yaodong Song
    Qiaofang Wang
    Yanna Liu
    Zhongwei Wu
    Xiaojia Duan
    Yan Zhang
    Xiuqian Bi
    Yuanzhang Geng
    Sanyang Chen
    Changju Zhu
    Scientific Reports, 11
  • [37] Melatonin ameliorates osteoarthritis rat cartilage injury by inhibiting matrix metalloproteinases and JAK2/STAT3 signaling pathway
    Zhao, Zhongyuan
    Bi, Benjun
    Cheng, Gong
    Zhao, Yuchi
    Wu, Hao
    Zheng, Mingdi
    Cao, Zhilin
    INFLAMMOPHARMACOLOGY, 2023, 31 (01) : 359 - 368
  • [38] Glycyrrhetinic acid triggers a protective autophagy by inhibiting the JAK2/ STAT3 pathway in cerebral ischemia/reperfusion injury
    Liang, Jian-feng
    Qin, Xiao-dan
    Huang, Xue-hong
    Fan, Zi-ping
    Zhi, Yong-ying
    Xu, Jia-wei
    Chen, Fangmei
    Pan, Zhi-li
    Chen, Yi-fei
    Zheng, Chang-bo
    Lu, Jun
    NEUROSCIENCE, 2024, 554 : 96 - 106
  • [39] FOXO1 Alleviates Liver Ischemia-reperfusion Injury by Regulating the Th17/Treg Ratio through the AKT/Stat3/FOXO1 Pathway (Vol 10, pg 1138, 2022)
    Ren, Hao-Zhen
    Xia, Sen-Zhe
    Qin, Xue-Qian
    Hu, An-Yin
    Wang, Jing-Lin
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (06) : 1443 - 1443
  • [40] Melatonin ameliorates osteoarthritis rat cartilage injury by inhibiting matrix metalloproteinases and JAK2/STAT3 signaling pathway
    Zhongyuan Zhao
    Benjun Bi
    Gong Cheng
    Yuchi Zhao
    Hao Wu
    Mingdi Zheng
    Zhilin Cao
    Inflammopharmacology, 2023, 31 : 359 - 368